Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Pharmacodynamics
- Acronyms GIRAF
- 23 Mar 2019 Planned End Date changed from 1 Mar 2021 to 23 Mar 2021.
- 23 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 23 Mar 2020.
- 23 Mar 2019 Status changed from recruiting to active, no longer recruiting.